Tecartus, Kite’s CAR-T cell therapy for relapsed or refractory mantle cell lymphoma, is to be made available to patients on the National Health Service in England under interim funding via the country's Cancer Drugs Fund.
Health technology assessment (HTA) body NICE today said it had recommended access through the temporary funding mechanism rather than via...








